.jpg)
January 15, 2024 – Backstop Neural, a pioneer in the development of the world’s first thin film-based spinal cord stimulator (SCS) paddle lead, is thrilled to announce the appointment of Dr. Peter Staats to its Advisory Board. Dr. Staats, a renowned pain management physician and founder of the division of Pain Medicine at Johns Hopkins University, brings a wealth of clinical expertise and industry leadership to BackStop Neural’s goal of revolutionizing chronic pain treatment.
“Dr. Staats’s addition to our Technology Advisory Board is a significant milestone in our journey to bring transformative pain relief to patients suffering from chronic spinal cord conditions,” said BackStop Neural Chief Product Officer Kial Gramley. “His deep understanding of the needs of patients and his extensive experience in evaluating innovative medical technologies will be invaluable as we refine our thin-film SCS technology and prepare it for clinical trials.”
Dr. Staats has dedicated his career to improving the lives of patients suffering from chronic pain. He is a board-certified pain management physician with over 20 years of experience, recognized for his expertise in minimally invasive interventional procedures and his commitment to patient-centered care. He has served in leadership roles at prestigious medical institutions and is a past president of the North American Neuromodulation Society and the American Society of Interventional Pain Physicians.
“I am excited to join BackStop Neural’s Advisory Board and contribute to the development of this groundbreaking SCS lead technology,” said Dr. Staats. “The potential to offer patients a thinner, conformal, and power-efficient solution for chronic pain is truly inspiring. I believe BackStop Neural’s technology has the potential to significantly improve the quality of life for patients, and I am committed to supporting their efforts to bring it to market.”
BackStop Neural’s SCS paddle lead featuring thin film electrodes and a softening polymer is designed to overcome the limitations of traditional SCS leads, which are bulky and invasive. The 10× thinner design conforms more closely to the spinal cord, potentially leading to improved efficacy and reduced scarring. This innovative technology has the potential to revolutionize the treatment of chronic pain, offering patients a new non-pharmacological option for managing their condition.
Dr. Staats joins a distinguished team of experts on BackStop Neural’s Advisory Board, further strengthening the company’s commitment to scientific rigor and innovation. With his expertise and guidance, BackStop Neural is poised to make significant strides in its quest to alleviate chronic pain and improve the lives of patients worldwide.
About BackStop Neural
BackStop Neural is a pioneering medical device company that specializes in developing advanced spinal cord stimulation solutions for individuals suffering from chronic pain. Through proprietary materials and neurostimulation technology, the company strives to provide patients with a renewed sense of hope and freedom from debilitating conditions. With a team of dedicated experts and a patient-centered approach, BackStop Neural aims to transform the landscape of neurology and elevate the standard of patient care.
For media inquiries, please contact:
Kial Gramley, Chief Product Officer
(956) 219-6752
Comments